Uveitis Treatment Market: Current Analysis and Forecast (2021-2027)

Uveitis Treatment Market: Current Analysis and Forecast (2021-2027)

The uveitis treatment market is expected to witness a CAGR of around 6% during the forecast period (2021–2027). Uveitis (chorioretinitis) is an inflammation of the middle layer of the eye for this complication the most common type is an inflammation of the iris called iritis (anterior uveitis). The major symptoms include redness, pain, light sensitivity, blurred vision, and dark floating spots in the field of vision. The common treatment for uveitis is eye drops, antibiotics or antiviral medication may be prescribed. As per WHO, lifestyle changes and urbanization will also dramatically increase the number of people with eye conditions, vision impairment, and blindness in the coming decades. For instance, On the basis of a study on medical records from California communities, uveitis leads to 30,000 new cases of blindness each year contributing to nearly 10% of all the blind cases.

AbbVie Inc., Alimera Sciences Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc., Clearside Biomedical Inc., EyePoint Pharmaceuticals Inc., Mylan N.V., Novartis AG, Santen Pharmaceutical Co. Ltd. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with the new and advanced uveitis treatment.

Insights Presented in the Report
"Amongst Drug Class, the anti-inflammatory category accounted for the majority share in the market in 2020”

Based on drug class, the uveitis treatment market is segmented into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. The anti-inflammatory category is anticipated to witness a significant growth rate during the forecast period. Anti-inflammatory medicines are used in the eyes to reduce problems that can occur during or after eye surgeries or treatment. Furthermore, this is mainly due to rising cases of cataracts, glaucoma, band keratopathy, autoimmune and inflammatory illnesses, etc. these factors are driving the growth of the uveitis treatment market during the forecast period. For instance, The Food and Drug Administration (FDA) has approved YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis.
"Amongst Diseases Type, the anterior uveitis category accounted for the majority share in the market in 2020”

Based on disease type, the uveitis treatment market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and pan uveitis. The anterior uveitis category is anticipated to witness a significant growth rate during the forecast period. Moreover, posterior uveitis is expected to witness lucrative growth during the study period owing to the availability of various drugs. Furthermore, the prevalence of the growth of this segment is mainly due to rising eye diseases such as glaucoma, retinal edema, autoimmune or inflammatory disease, decreased vision, etc. For instance, according to an article published by the Ocular Immunology and Uveitis Foundation in April 2022, uveitis afflicts 109,000 people in the U.S. and 43,000 new cases are diagnosed.
"Amongst Distribution Channel, the hospital pharmacies category is expected to witness the highest CAGR during the forecast period”

Based on distribution channel, the uveitis treatment market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The hospital pharmacies category is anticipated to witness a significant growth rate during the forecast period. This category is especially driven by the higher number of patients with eye-related complications and the availability of healthcare professionals in hospitals. However, the online pharmacy segment is expected to witness significant CAGR owing to the growing penetration of e-pharmacy platforms across the world coupled with increasing awareness regarding services offered by e-pharmacy. Furthermore, the growing focus on digitization and rising internet penetration in developing are some other key factors driving the category’s growth.
"North America to witness significant growth during the forecast period”

For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Rest of Asia-Pacific) and Rest of World. In 2020, North America accounted for a considerable market share. This is mainly due to the rising cases of uveitis and related diseases coupled with well-established healthcare infrastructure and rising healthcare expenditure across the region. For instance, according to the Canadian Institute for Health Information (CIHI), total health spending in Canada is expected to reach a new level in 2021, at more than $308 billion, or $8,019 per Canadian. It is anticipated that health expenditure will represent 12.7% of Canada’s gross domestic product (GDP) in 2021, following a high of 13.7% in 2020.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.